Dianthus Therapeutics, Inc.
DNTH
Clasificación en acciones
#3914
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Precio por acción
$75.21
Capitalización bursátil
$4.21B
Cambio (1 día)
4.33%
Cambio (1 año)
110.98%
País
US
Comercio Dianthus Therapeutics, Inc. (DNTH)
Categoría
Healthcare
Ratio P/S de Dianthus Therapeutics, Inc. (DNTH)
Ratio P/S al October 2026 TTM: 2.20K
Según los informes financieros más recientes y el precio de las acciones de Dianthus Therapeutics, Inc., el ratio P/S actual (TTM) es 2.20K. Al final de 2023, el ratio P/S era 18.97.
Historial del ratio P/S de Dianthus Therapeutics, Inc. desde 2016 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| 2026 (TTM) | 2.20K | 1,785.51% |
| 2024 | 116.48 | 514.17% |
| 2023 | 18.97 | 413.89% |
| 2022 | 3.69 | -97.76% |
| 2021 | 164.92 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | -99.54% |
US
|
|
| 40.55 | -98.15% |
US
|
|
| 3.96 | -99.82% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.54% |
NL
|
